Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences, Inc. (RNA) Total Current Liabilities (2019 - 2025)

Avidity Biosciences' Total Current Liabilities history spans 7 years, with the latest figure at $195.4 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 99.4% year-over-year to $195.4 million; the TTM value through Dec 2025 reached $195.4 million, up 99.4%, while the annual FY2025 figure was $195.4 million, 99.4% up from the prior year.
  • Total Current Liabilities reached $195.4 million in Q4 2025 per RNA's latest filing, up from $169.9 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $195.4 million in Q4 2025 to a low of $16.3 million in Q2 2021.
  • Average Total Current Liabilities over 5 years is $70.1 million, with a median of $50.3 million recorded in 2022.
  • Peak YoY movement for Total Current Liabilities: surged 106.19% in 2022, then increased 13.22% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $29.7 million in 2021, then skyrocketed by 75.02% to $51.9 million in 2022, then skyrocketed by 55.43% to $80.7 million in 2023, then grew by 21.49% to $98.0 million in 2024, then surged by 99.4% to $195.4 million in 2025.
  • Per Business Quant, the three most recent readings for RNA's Total Current Liabilities are $195.4 million (Q4 2025), $169.9 million (Q3 2025), and $135.1 million (Q2 2025).